PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Price, Quote, News and Overview
NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
PLX Quote, Performance and Key Statistics
1.59
+0.03 (+1.92%)
The current stock price of PLX is 1.59 USD. In the past month the price decreased by -46.28%. In the past year, price increased by 40.71%.
PLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.83 | 323.41B | ||
| AMGN | AMGEN INC | 13.41 | 149.70B | ||
| GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
| ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
| ONC | BEIGENE LTD-ADR | 6.16 | 25.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
| NTRA | NATERA INC | N/A | 22.01B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
| BIIB | BIOGEN INC | 8.06 | 18.69B |
Related stock screener links
About PLX
Company Profile
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 207 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Company Info
PROTALIX BIOTHERAPEUTICS INC
2 University Plaza, Suite 100
Hackensack NEW JERSEY 07601 US
CEO: Dror Bashan
Employees: 213
Phone: 12016969345
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the stock price of PROTALIX BIOTHERAPEUTICS INC today?
The current stock price of PLX is 1.59 USD. The price increased by 1.92% in the last trading session.
What is the ticker symbol for PROTALIX BIOTHERAPEUTICS INC stock?
The exchange symbol of PROTALIX BIOTHERAPEUTICS INC is PLX and it is listed on the NYSE Arca exchange.
On which exchange is PLX stock listed?
PLX stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for PROTALIX BIOTHERAPEUTICS INC stock?
5 analysts have analysed PLX and the average price target is 14.79 USD. This implies a price increase of 830.19% is expected in the next year compared to the current price of 1.59. Check the PROTALIX BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROTALIX BIOTHERAPEUTICS INC worth?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a market capitalization of 126.58M USD. This makes PLX a Micro Cap stock.
How many employees does PROTALIX BIOTHERAPEUTICS INC have?
PROTALIX BIOTHERAPEUTICS INC (PLX) currently has 213 employees.
What are the support and resistance levels for PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a support level at 1.5 and a resistance level at 1.72. Check the full technical report for a detailed analysis of PLX support and resistance levels.
Is PROTALIX BIOTHERAPEUTICS INC (PLX) expected to grow?
The Revenue of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 61.73% in the next year. Check the estimates tab for more information on the PLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PLX, evaluating the profitability, health, valuation and growth aspects
- PROTALIX BIOTHERAPEUTICS INC (PLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROTALIX BIOTHERAPEUTICS INC (PLX) Sales and EPS estimates to see what analysts future expectations are.
- PROTALIX BIOTHERAPEUTICS INC (PLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROTALIX BIOTHERAPEUTICS INC (PLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Chart to make your own analysis
- PROTALIX BIOTHERAPEUTICS INC (PLX) Latest news and press-releases to stay up to date.
Does PROTALIX BIOTHERAPEUTICS INC (PLX) stock pay dividends?
PLX does not pay a dividend.
When does PROTALIX BIOTHERAPEUTICS INC (PLX) report earnings?
PROTALIX BIOTHERAPEUTICS INC (PLX) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of PROTALIX BIOTHERAPEUTICS INC (PLX)?
The PE ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 39.75. This is based on the reported non-GAAP earnings per share of 0.04 and the current share price of 1.59 USD. Check the full fundamental report for a full analysis of the valuation metrics for PLX.
What is the Short Interest ratio of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
The outstanding short interest for PROTALIX BIOTHERAPEUTICS INC (PLX) is 1.48% of its float. Check the ownership tab for more information on the PLX short interest.
PLX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PLX. When comparing the yearly performance of all stocks, PLX turns out to be only a medium performer in the overall market: it outperformed 67.26% of all stocks.
PLX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PLX. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here.
PLX Financial Highlights
Over the last trailing twelve months PLX reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.54% | ||
| ROA | 5.29% | ||
| ROE | 8.64% | ||
| Debt/Equity | 0 |
PLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PLX. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 943.67% and a revenue growth 61.73% for PLX